On March 18, 2026, MetaVia Inc. announced the approval of a Phase 1 Part 3 clinical trial for its obesity drug DA-1726 by the Institutional Review Board at Clinical Pharmacology of Miami, to enroll 40 participants.
AI Assistant
METAVIA INC
2026
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.